Skip to main content

Table 2 Clinical remission in JIA patients treated with DMARD according to treatment group. Retrospective study results

From: Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach

  SDMARD alone
n = 106 (53%)
SDMARD combined
n = 37 (19%)
SDMARD BDMARD combined
n = 48 (24%)
BDMARD alone
n = 8 (4%)
Clinical remission
n = 199
p
JIA ILAR category a n (%)
 Oligoarticular 66 (62) 18 (49) 25 (52) 3 (1) 112 (56) 0.003
  Persistent 61 (92) 13 (72) 17 (68) 1 (33) 92 (82)  
HLA B27 absence a n (%) 89 (84) 33 (89) 25 (52) 6 (75) 153 (85) 0,023
Synthetic DMARD a n (%)
 Metotrexate 78 (74) 18 (49) 15 (31) 0 108 (54) < 0.001
No AE with DMARD a n (%) 81 (76) 24 (65) 33 (69) 1 (13) 139 (70) 0.005
Dose tapering n = 132
 Dose tapering a n (%) 80 (75) 18 (49) 29 (60) 5 (62) 132 (66) 0,018
  Tapering method n (%)       0,071
   Interval increase 35 (44) 8 (44) 12 (41) 5 (100) 60 (45)  
   Dose decrease 30 (37) 7 (39) 15 (31) 0 46 (35)  
   Both 15 (19) 3 (17) 1 (3) 0 19 (14)  
  Tapering duration, months, median (IQR) 15 (20) 14 (27) 21 (25) 40 (30) 16 (28) 0,190
  Relapse amid tapering, n (%) 10 (13) 5 (28) 4 (14) 0 19 (14) 0,330
  Withdrawal after tapering a, n (%) 69 (86) 16 (89) 10 (34) 1 (13) 95 (72) < 0,001
Withdrawal due to CR n = 124
 Withdrawal due to CR 71 (67) 29 (78) 21 (44) 3 (38) 124 (62) 0,728
  Treatment duration to withdrawal due to RC a, months, median (IQR) 31 (26) 42 (43) 34 (54) 68 (71) 31 (30) 0,037
  Relapse after withdrawal n (%) 50 (70) 16 (55) 11 (52) 2 (67) 79 (64) 0,783
  Time to relapse, months, median (IQR) 13 (25) 42 (41) 10 (18) 14 14 (32) 0,122
  1. SDMARD Synthetic disease modifying drug, BDMARD Biologic disease modifying drug, JIA Juvenile idiopathic arthritis, n Number, HLA B27 Human leukocyte antigen, AE Adverse event, IQR Interquartile range, CR Clinical remission
  2. ap < 0,05 Statistically significant differences using the χ2 or Mann Whitney U tests